OncoMatch/Clinical Trials/NCT03844360

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Is NCT03844360 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments for hematological neoplasms.

Phase 4RecruitingWei ZhaoNCT03844360Data as of May 2026

Treatment: Bortezomib · Eltrombopag · Imatinib · dasatinib · Pegaspargase · Anti-Infective Drugs · PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor — The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

Check if I qualify

Eligibility summary

For patients with Hematologic Neoplasm.

This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify